• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Society for Women’s Health Research urges FDA to require trials to examine gender-based differences

Society for Women’s Health Research urges FDA to require trials to examine gender-based differences

April 2, 2014
CenterWatch Staff

Seeking to increase the participation of women and minorities in all phases of clinical trials, along with greater reporting and analysis of gender differences, Phyllis Greenberger testified at an FDA hearing yesterday. She presented a series of recommendations and changes to how the agency handles the collection, analysis and availability of demographic subgroup data in applications for FDA-regulated medical products.  

Greenberger is president and CEO of the Society for Women’s Health Research, which has advocated for more research into biological differences and for the reporting and analysis of gender and ethnic differences to help transform science and the quality of care.

“During the last two decades, there have been many advances and tremendous discoveries in how diseases and illnesses impact women differently, disproportionately and exclusively from men,” said Greenberger. “Nevertheless, women and minorities remain chronically under-represented in medical research. “

She cited the NIH’s efforts to recruit and retain women and minorities in phase III trials, but said it does not extend to earlier phases or to basic research, which garners the vast majority of funding. Biological and physiological differences and hormonal fluctuations play a role in the rate of drug absorption, distribution, metabolism and elimination, she said, as well as the ultimate effectiveness in females compared to males.

“This should be discovered in the clinical trials, not after a drug reaches the marketplace,” said Greenberger.

She cited the FDA’s order, early last year, that the manufacturers of sleep medication Ambien lower the recommended dose for women after a series of clinical trials and driving simulation studies revealed the drug’s active ingredient stayed in women’s systems longer,  impairing their alertness after waking up, including the ability to drive.

Among the Society’s recommendations to the FDA:

  • Establish disease-specific registries with dedicated funding to encourage those affected to sign up for medical studies and include incentives to keep them engaged in the research process
  • Women, minorities and the elderly should be included in all phases of clinical research
  • Labels should inform these populations when they are using drugs or devices that have not been sufficiently tested on them
  • Establish training for all reviewers to look for gender differences and other demographic data, along with re-training at regular intervals
  • Drug and device applications that include the appropriate subpopulation representation should be put on a fast track for approval; applications without these groups should be rejected, as post-market surveillance should not substitute for what may be discovered in the pre-market approval process.

Greenberger also urged the FDA to work with patient groups and sponsors to address existing knowledge gaps to capture all potential information in a clinical trial. If new drug applications must include appropriate subpopulation representation and analysis, clinical trial participation will change at all phases and less will be discovered post market, often years after approval and use.

“Facts regarding sex differences,” she said, “such as women suffering more side effects and more adverse events, should not be discovered post market.” 

—Ronald Rosenberg, CenterWatch Staff Writer

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing